Skip to main content

Table 3 Antimicrobials used for the patients with carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis bacteremia*

From: Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis

Main agents used No. of patients APACHE II score No. (%) of patients
   Median (interquartile range) Appropriate antimicrobial therapy 14–day mortality
Anti-pseudomonal penicillinsa
CRAB 12 31.5(22.8–39.0) 2(16.7) 6(50.0)
CRAN 8 24(19.0–33.0) 7(87.5) 2(25.0)
Anti-pseudomonal cephalosporinsb
CRAB 14 26(22.8–34.0) 2(14.3) 4(28.6)
CRAN 10 26(19.3–30.0) 7(70.0) 1(10.0)
Anti-pseudomonal fluoroquinolonesc
CRAB 5 30(21.0–36.0) 1(20.0) 2(40.0)
CRAN 2 37.5(37.0–38.0) 2(100.0) 0(0)
Anti-pseudomonal carbapenemsd
CRAB 17 32(24.0–38.5) 0(0) 7(41.2)
CRAN 14 30.5(23.0–33.3) 0(0) 2(14.3)
Ampicillin/sulbactam or sulbactam
CRAB 11 17(15.0–33.0) 4(36.4) 5(45.5)
CRAN 8 24(18.0–27.5) 3(37.5) 0(0)
Non-antipseudomonal β-lactamasese
CRAB 6 17.5(15.3–25.3) 0(0) 1(16.7)
CRAN 9 18(15.5–24.0) 3(33.3) 1(11.1)
Miscellaneous
CRAB 6 25(17.8–32.0) 0(0) 2(33.3)
CRAN 13 27(16.0–35.5) 0(0) 3(23.1)
  1. *Data are median value (interquartile range) for continuous variables and number of cases (%) for categorical variables. aIncluding piperacillin, piperacillin/tazobactam, and ticarcillin/clavulanate. bIncluding cefoperazone, ceftazidime, cefepime, and cefpirome. cIncluding ciprofloxacin and levofloxacin. dIncluding imipenem and meropenem. eIncluding penicillin, amoxicillin/clavulanate, cefazolin, cefuroxime, cefotaxime, cefmetazole, and flomoxef. APACHE II Acute Physiologic and Chronic Health Evaluation II, CRAB carbapenem resistant A. baumannii, CRAN carbapenem resistant A. nosocomialis.